Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 5.

Journal Article

Al-Sawaf, O., Robrecht, S., Fink, A., Ritgen, M., Johansson, P., Staber, P., Jaeger, U., Niemann, C., Pallasch, C., Kreuzer, K., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M. and Eichhorst, B. (2020). The CLL-RT1 trial: A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation. Oncol. Res. Treat., 43 (SUPPL 4). S. 73 - 74. BASEL: KARGER. ISSN 2296-5262

Kreuzer, K., Stuhlmann, R., Lebioda, A., Reitan, J., Barber, B. L. and Barlev, A. (2015). HOSPITALISATIONS AMONG ADULT PATIENTS WITH PH-NEGATIVE B-PRECURSOR RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) RECEIVING CHEMOTHERAPY IN GERMANY: A RETROSPECTIVE CHART REVIEW. Value Health, 18 (7). S. A443 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1524-4733

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Weiss, J., Knuver, J., Schlaak, M., Kreuzer, K., Hallek, M. and Mauch, C. (2016). Minimal-invasive tumor monitoring of BRAF V600E positive tumors in cell-free plasma DNA. J. Dtsch. Dermatol. Ges., 14. S. 11 - 13. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387

This list was generated on Tue Apr 16 18:53:38 2024 CEST.